Alcoholism

The Magdalen House Opens Men's Program in East Dallas

Retrieved on: 
Wednesday, January 17, 2024
Alcoholism, Woman, Volunteering, First Step, Senior counsel, Drinking, Health, Next Step, Knowledge, Family support, Education, D/FW, Prevalence, Recycling

DALLAS, Jan. 17, 2024 /PRNewswire/ -- After 36 years of supporting women struggling with alcoholism and their families, The Magdalen House is thrilled to open the doors to their Men's Program facility in Dallas. This beloved North Texas nonprofit has extended its commitment to helping the alcoholic community by including men. It will offer high-quality services mirroring those of its established women's program, utilizing the principles of 12 Step recovery—all at no charge.

Key Points: 
  • DALLAS, Jan. 17, 2024 /PRNewswire/ -- After 36 years of supporting women struggling with alcoholism and their families, The Magdalen House is thrilled to open the doors to their Men's Program facility in Dallas.
  • The house can accommodate up to 12 men with rolling admissions for their First Step program.
  • The Magdalen House is committed to help individuals achieve long-term, sustainable recovery through the following spiritually based, comprehensive programs:
    First Step program : A two-week, residential program for an individual with alcoholism who wants to stop drinking but cannot.
  • Next Step program : A three-phase, nonresidential program for an individual with alcoholism at any stage of recovery.

Mindpath Health releases Holiday Hangover: Why Dry January May Be Right for You

Retrieved on: 
Wednesday, January 10, 2024
Headache, Drink, Woman, Alcohol Change UK, Alcoholism, Binge drinking, Drinking, Social media, Sleep, TMS, Holiday, Life, Health, Seizure, Multimedia, Judgement, Perspiration, Friends, Heartburn, USDA, Anxiety, Psychiatry, CDC, Skin, Sobriety, Wine, Liquid Death, Christmas Eve, Psychology, Physician, DNP, News, Depression, Dizziness, Growth, Nursing

You've probably heard of Dry January if you've been on social media in the last ten years.

Key Points: 
  • You've probably heard of Dry January if you've been on social media in the last ten years.
  • Though plenty of apps help track your progress, Dry January is as low-tech as you want it to be.
  • This article was written by Andrew Monasterio, PMHNP-BC, DNP, a board-certified psychiatric nurse practitioner with Mindpath College Health in Isla Vista, California.
  • Mindpath Health is a leading provider of high-quality outpatient behavioral health services, offering in-person and telehealth visits.

Hydration Reimagined: Corpse Reviver Introduces a Revival Blend That Essentializes Your Daily Well-Being

Retrieved on: 
Tuesday, January 9, 2024
Drink, Electrolyte, Alcoholism, Heart, Cadaver, Corpse reviver, Botany, Alchemy, Reviver, Prickly pear, General partnership

DENVER, Jan. 9, 2024 /PRNewswire/ -- Corpse Reviver, the woman-owned beverage brand, is thrilled to introduce the captivating launch of its Hydration Libation. After starting their sister brand Hooch Booch in 2020, founder Anna Zesbaugh realized there was an opportunity to offer better-for-you beverages in both the alcohol and non-alcoholic space. This brand was inspired by a growing desire in society to step into every day with your best foot forward. This electrolyte beverage has three unique flavors (Botanical, Guava Rose, and Prickly Pear). Get ready to indulge in a revitalizing experience designed for daily use.

Key Points: 
  • Corpse Reviver is thrilled to unveil its "Hydration Libation," a daily revival blend of electrolytes, real ingredients, and essential elements.
  • DENVER, Jan. 9, 2024 /PRNewswire/ -- Corpse Reviver, the woman-owned beverage brand, is thrilled to introduce the captivating launch of its Hydration Libation.
  • This brand was inspired by a growing desire in society to step into every day with your best foot forward.
  • We dove headfirst into crafting our Corpse Reviver, your daily dose of electrolytes packed into a can.

CobbleStone Software Interviews Outreach Coordinator for Lawyers, Brian S. Quinn

Retrieved on: 
Monday, January 8, 2024
Interview, CLM, Marketing, Cobblestone, CLE, SPARK, Lawyer, Mental health, Software, Alcoholism, Education

PRINCETON, N.J., Jan. 8, 2024 /PRNewswire-PRWeb/ -- CobbleStone Software – a recognized Leader in contract lifecycle management (CLM) according to the SPARK Matrix™ 2023 Report– recently met with Brian following their successful CLE webinar and was able to gain some insights into issues lawyers and legal professionals may face in the industry.

Key Points: 
  • CobbleStone® has recently interviewed Brian S. Quinn – the speaker of their last educational webinar and licensed attorney in Pennsylvania.
  • "After the success of our webinar, we are thrilled to work with him again and gain some insight on this topic.
  • During the interview, Brian explores legal professional burnout, mental health, and what can help for prevention.
  • Contact CobbleStone Software to schedule a free demo.

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Kidney, Metabolic acidosis, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases

Retrieved on: 
Thursday, January 4, 2024
FDA, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Alcoholism, Atopic dermatitis, Cholesterol, Metabolism, Multimedia, IND, Alcoholic hepatitis, Disease, Mortality, AMD, Body surface area, Therapy, MELD, Clinical trial, Hospital, Telecanthus, DSM-IV codes, Spasticity, Protocol, Cirrhosis, Biomarker, Triglyceride, Syndrome, Ethanol, Patient, Safety, RASP, Retina, Pharmaceutical industry

ADX-629, administered twice daily over 90 days, has completed initial clinical testing in three adult patients in an investigator-sponsored clinical trial.

Key Points: 
  • ADX-629, administered twice daily over 90 days, has completed initial clinical testing in three adult patients in an investigator-sponsored clinical trial.
  • Highlighting the advancement of the RASP platform and the selection of key clinical indications for future development, Aldeyra released a focused pipeline.
  • “With the success achieved in our ADX-629 program, which includes a number of positive, signal-finding clinical results, we are excited to advance our RASP modulator pipeline to systemic and retinal immune-mediated diseases, as well as metabolic diseases, exacerbated by RASP,” stated Dr. Brady.
  • “We anticipate 2024 to provide a variety of clinical-stage catalysts, as Aldeyra continues to progress its novel RASP platform.”

Mario Gonzalez Wrongful Death Case Against Alameda Officers Settles for $11 Million

Retrieved on: 
Friday, December 15, 2023
Autopsy, Risk, Asphyxia, Police, City, Brain, Swelling, Seizure, Methamphetamine, Death, Homicide, Oxygen, Immunity, Officer, Obesity, Congestion, Alcoholism, Human, Torso, Pressure, Magistrate, Drug

The parties then negotiated this settlement, which was approved by the Alameda City Council and its insurers last night, December 14.

Key Points: 
  • The parties then negotiated this settlement, which was approved by the Alameda City Council and its insurers last night, December 14.
  • Officer McKinley asked Mario Gonzalez how he was doing, and Mr. Gonzalez responded that he was fine, although he appeared confused and disoriented.
  • Officers’ body-camera video shows officers placing Mr. Gonzalez in multiple pain compliance holds before they forced him face-down on the ground.
  • Officers forced Mr. Gonzalez into a prone position, and Officers McKinley and Fisher held him down with their force and body weight.

Newmark Represents DrinkPAK in Two New Industrial Leases in Fort Worth, Totaling 2.9 Million Square Feet

Retrieved on: 
Monday, December 18, 2023
Associate, Tenant, Drink, Alcoholism, DFW, Trammell Crow, Growth, Clarion Partners, Organization, History, Senior, Sales

DALLAS, Dec. 18, 2023 /PRNewswire/ -- Newmark announces that DrinkPAK, a canned beverage manufacturer headquartered in California, has closed on two industrial leases totaling 2.9 million square feet in its expansion to Fort Worth, Texas, nearly tripling the company's real estate footprint. These leases represent the largest new industrial occupier leasing commitment completed in a single market across the U.S. this year and are projected to create 1,000 full-time jobs in the area by 2026. Additionally, the city has approved a 10-year tax abatement valued at $21 million for DrinkPAK's expansion in support of the area's long-term development.

Key Points: 
  • Additionally, the city has approved a 10-year tax abatement valued at $21 million for DrinkPAK's expansion in support of the area's long-term development.
  • Newmark has played a pivotal role in aiding DrinkPAK's expansion since 2020, securing multiple leases totaling over 1.5 million square feet in the North Los Angeles region.
  • "We are thrilled to have played a crucial advisory role in securing two monumental leases on behalf of DrinkPAK.
  • Newmark is honored be a part of DrinkPAK's growth journey and to assist the company in realizing its vision."